← All trials
NCT05821595
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 31, 2023
- Primary completion
- Sep 15, 2024
- Completion date
- Oct 31, 2024
- First posted
- Apr 20, 2023
- Last posted
- Jun 27, 2023
- Enrollment
- 30
- Arms / groups
- 5 / —
- Source
- AACT · ctgov ingestion
Sponsors
- JemincareLead sponsor
- Chinese Academy of Medical SciencesOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.